和黄医药（HUTCHMED）已决定从中国大陆、香港及澳门市场全面撤回其肿瘤靶向药物Tazverik®（泰泽凯®）。此项商业决策与产品撤回同步，公司同时宣布将终止该药物所有正在进行的临床试验项目。此举标志着泰泽凯®在大中华区的临床开发与商业化进程暂告段落。
和黄医药（HUTCHMED）已决定从中国大陆、香港及澳门市场全面撤回其肿瘤靶向药物Tazverik®（泰泽凯®）。此项商业决策与产品撤回同步，公司同时宣布将终止该药物所有正在进行的临床试验项目。此举标志着泰泽凯®在大中华区的临床开发与商业化进程暂告段落。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.